Research programme: CD40 agonists - Apogenix

Drug Profile

Research programme: CD40 agonists - Apogenix

Alternative Names: APG 1233; APG 1274; HERA-CD40L - Apogenix; scCD40L-RBD-Fc

Latest Information Update: 26 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apogenix
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action CD40 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 16 Apr 2018 Pharmacodynamics data from a preclinical trial in SOlid tumours presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 29 Nov 2016 Pharmacokinetics and Pharmacodynamics data from preclinical and in vitro studies presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 15 Dec 2015 Research programme: CD40 agonists - Apogenix is available for licensing as of 15 Dec 2015. www.apogenix.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top